Adam Riesselman is a computational biologist with experience in developing powerful, interpretable machine learning models for complex biological data. At insitro, Adam is focused on integrating high-throughput measurements with new scalable algorithms to understand disease.
Adam received a BA in Biochemistry: Cell and Molecular Biology from Drake University and his PhD in Biomedical Informatics at Harvard University with Debora Marks as a Department of Energy Computational Science Graduate Fellow. There he developed new statistical models for unsupervised mutation effect prediction from evolutionary data, de novo protein structure prediction via simulation, protein library design with improved biomolecular properties, and small molecule production optimization utilizing biosynthetic pathway engineering.
When not at the computer, Adam likes to cook and enjoy the outdoors by hiking, gardening, and biking.
As Vice President of High-throughput Biology Aj is responsible for producing high-quality data sets to use in for machine learning-based target and drug discovery. He leads insitro’s wet lab activities (bio-data factory) which consists of functional genomic, disease modeling, automation/process engineering and proteomic teams.
Ajamete has spent over 28 years in both industry and academia, working in the areas of proteomics, genomics, and stem cell biology. Before joining insitro, Aj led the early target discovery team at Novartis Institutes for Biomedical Research in the Neuroscience unit. His team efforts have led to the discovery of multiple new disease targets and the development of better predictive preclinical models. He conducted his postdoc with Dr. Randy Moon at University of Washington/Howard Hughes Medical Institute on Wnt-signaling. While in Randy’s lab, he conducted one of the first ever genome-wide RNAi screens and studied the role of Wnt-signaling in human disease and stem cell biology. He did his graduate work at University of Wisconsin-Madison in Dr. Bill Sugden’s lab where he studied virology, immunology, and oncology.
In his free time, Aj enjoys traveling, kayaking, sailing, biking, making whiskey and most of all his family.
Selected Publications:DRUG-seq: A Miniaturized High-Throughput Transcriptome Profiling Platform for Drug Discovery. Ye C, Ho DJ, Neri M, Yang C, Kulkarni T, Randhawa R, Henault M, Mostacci N, Farmer P, Renner S, Ihry R, Mansur L, Gubser Keller C, McAllister G, Hild M, Jenkins J, and Kaykas A. In Press, Sept; 2018 Nat. Comm. https://www.nature.com/articles/s41467-018-06500-x p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Ihry RJ, Worringer KA, Salick MR, Frias E, Ho D, Theriault K, Kommineni S, Chen J, Sondey M, Ye C, Randhawa R, Kulkarni T, Yang Z, McAllister G, Russ C, Reece-Hoyes J, Forrester W, Hoffman GR, Dolmetsch R, Kaykas A. Nat Med. 2018 Jul;24(7):939-946. https://www.nature.com/articles/s41591-018-0050-6 A Single-Cell Roadmap of Lineage Bifurcation in Human ESC Models of Embryonic Brain Development. Yao Z, Mich JK, Ku S, Menon V, Krostag AR, Martinez RA, Furchtgott L, Mulholland H, Bort S, Fuqua MA, Gregor BW, Hodge RD, Jayabalu A, May RC, Melton S, Nelson AM, Ngo NK, Shapovalova NV, Shehata SI, Smith MW, Tait LJ, Thompson CL, Thomsen ER, Ye C, Glass IA, Kaykas A, Yao S, Phillips JW, Grimley JS, Levi BP, Wang Y, Ramanathan S. Cell Stem Cell. 2017 Jan 5;20(1) https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(16)30340-X?code=cell-site Genetic Ablation of AXL Does Not Protect Human Neural Progenitor Cells and Cerebral Organoids from Zika Virus Infection. Wells MF, Salick MR, Wiskow O, Ho DJ, Worringer KA, Ihry RJ, Kommineni S, Bilican B, Klim JR, Hill EJ, Kane LT, Ye C, Kaykas A*, Eggan K.* Cell Stem Cell. 2016 Dec 1;19(6):703-708. *Co-corresponding author https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(16)30407-6 Functional genomic analysis of the Wnt-wingless signaling pathway. DasGupta R*, Kaykas A*, Moon RT, Perrimon N. Science. 2005 May 6;308(5723):826-33. *Co-first authors https://science.sciencemag.org/content/308/5723/826
Albert utilizes different automation technologies to ensure quality data generation from many of insitro’s scientific processes. This includes integrating specific assays onto automation, onboarding tools for efficient execution, and maintaining an environment for seamless research operations.
After graduating with his B.S. in Biochemistry and Philosophy from Wisconsin-Madison he started at Abbott Laboratories as an Associate Scientist focusing on instrument and assay validation for their diagnostics platform. After working in a big company environment, he joined Transcriptic, where he helped w/ assay integration and automation.
In his free time, Albert enjoys watching the NBA and trying out different banana bread recipes.
Alice Starr is a software engineer, with experience designing and architecting scientific research applications. At insitro, Alice is focused on laboratory information and data architecture, making sure we make the most of our generated data. Prior to insitro, she was at Genentech, designing data solutions for the translational research and pathology organizations. She loves to tackle data challenges to advance science, which provides constant opportunities to learn.
Alice received a BS and MS in Mathematics and Computer Science from EPF, France and ITESM, Mexico.
When not working or playing with her two daughters, Alice likes to read and be outdoors as much as possible, walking or running on the beautiful California trails.
Alicia is Senior Research Associate in High-Throughput Biology and she is working on differentiating iPSCs into appropriate cell types for disease modeling to produce data sets for insitro’s machine learning platform.
Prior to joining insitro, Alicia was working on cell therapies for neurodegenerative diseases at Neurona Therapeutics. Before then she was at the Gladstone Institutes working on cellular models of neurodegenerative diseases. Alicia has a bioengineering background and obtained her B.S. and M. Eng. in Bioengineering from UCSD.
In her spare time, Alicia enjoys reading, hiking and traveling.
Britt Huber is the Vice President of People at insitro. She brings with her over 15 years of experience in People Operations / Human Resources, Organizational Development and business management leadership roles, in
the life sciences and technology industries, both in California and in Switzerland. Britt is passionate about developing mission-driven companies and coaching its people to evoke excellence.
Prior to joining insitro, Britt served as VP, People & Organizational Development at PaxVax, Inc., a fully-integrated specialty vaccines company, which she helped build and scale from start-up to a global, commercial stage company that was acquired by Emergent BioSolutions in 2018. Before then, Britt was the VP of People at Kiva, the world’s first personal micro-lending platform, where she supported the organization’s doubling in size, internationalization, and creation of an awesome culture.
Britt holds an MBA from St. Mary’s College, Moraga, California and a Senior Professional in Human Resources (SPHR)-Certification. She’s also a Certified Professional Coach from New Ventures West, San Francisco, California. She speaks English, German, French, Italian, and Spanish.
When Britt is not cheer-leading the people she serves, she loves to explore the world traveling, enjoys the great outdoors while running, biking, hiking, swimming, skating,painting or striking a yoga pose somewhere.
Chris Probert is a computational biologist and computer scientist with extensive experience building deep learning models for genomic data. His current work at insitro is focused on enabling large-scale deep learning on functional genomic data produced by the high throughput biology platform.
Chris is a PhD candidate in Computational Biology (Genetics) at Stanford working with Anshul Kundaje and Christina Curtis where he was an NSF Fellow and an Accel Innovation Scholar. His PhD work focused on large-scale machine learning analysis of functional genomics datasets, including imputation and superresolution of genome-wide epigenomic signals, unsupervised methods for learning differentiation lineages in single-cell RNA-seq, and tissue of origin inference from cell-free DNA fragmentation patterns. He has extensive engineering experience building scalable infrastructure and data architectures to support distributed training of deep learning models from petabyte-scale functional genomic datasets. He also holds an MS and BS in Computer Science, and experience working in both research and product focused software engineering roles at Google, Illumina, and Counsyl.
Outside of work, Chris enjoys running, cycling, backpacking, and backcountry skiing.
Claire Jeong is a Scientist with various experiences and expertise in human cell-based complex in vitro models (i.e. 3D bioprinting, organs-on-chip, organoids) for drug discovery. At insitro, Claire is a Senior Scientist in the Disease Modeling Group and works on developing and implementing human relevant models and assays to generate more disease relevant data that enables machine-learning based drug discovery.
Prior to joining insitro, Claire was trained as a biomedical engineer and earned her B.S. from Johns Hopkins University and her M.S./Ph.D. from the University of Michigan-Ann Arbor, majoring in Biomedical Engineering with cartilage/bone tissue engineering and biomaterials focus. After her postdoctoral work at Duke University exploring stem cells and cell delivery for disc regeneration, she joined GSK for a collaborative project between GSK and Wake Forest Institute of Regenerative Medicine, and continued working as an investigator for the Complex In Vitro Models group part of the Platform Technology & Sciences division of GSK Pharma R&D.
She also did a secondment with the Accelerating Therapeutics for Opportunities in Medicine (ATOM) Consortium and served as co-lead on a safety integrated project team and as a complex in vitro models expert, to build integrated predictive safety, efficacy, and PK computational models for cancer drug discovery.
In her spare time, Claire enjoys playing the cello, yoga, hiking, reading, live music and performances and exploring new places and unique cuisines.
Cody Scandore is a process engineer with experience transitioning new technologies toward productive scientific research applications. As a member of the Process Engineering team at insitro, Cody works to enable the production of high quality biological data for downstream machine learning analysis and data science. He is frequently engaged in process transfer, process development, and developing the laboratory’s network infrastructure.
Cody began working in research and manufacturing roles supporting the production of high vacuum deposition tools for the semiconductor industry in 2012. Later, he joined the Genomics Institute of the Novartis Research Foundation, where he worked to scale biological assays using high-throughput robotic systems. Cody moved from GNF to the SF Bay Area to help early-stage companies industrialize exciting new techniques available to biologists, such as iPS cell culture & differentiation, genome engineering, and cerebral organoid production.
Cody holds a B.A. in Economics from Vassar College, a B.S. in Chemical Engineering from the University of Massachusetts, and is a CFA candidate.
Outside of work, Cody enjoys outdoor activities such as hiking and cycling.
As Scientific Specialist at Insitro, Craig will be working with the Disease Modeling group to help develop robust, scalable and highly reproducible in vitro models of human disease. Craig will also focus on integrating these models into high throughput, automated platforms to eliminate variability and provide large, trustworthy data sets to the Machine Learning team.
After graduating from the University of California Santa Barbara, Craig has supported various research and development efforts in Neuroscience, Stem Cell and Cancer Biology. Throughout his career, Craig has acquired an extensive research experience from institutions such as the Neuroscience Institute, UC San Diego, California Stem Cell Inc., and Memorial Sloan Kettering Cancer Center. Craig hopes to use his experience and ideas to help advance the exciting programs at Insitro to the next level of drug discovery.
Craig enjoys an occasional escape to the wilderness for fishing, camping, exploring and basically just having fun with family. Favorite author: Bertrand Russell.
Daphne Koller is the CEO and Founder of insitro.
Daphne was the Rajeev Motwani Professor of Computer Science at Stanford University, where she served on the faculty for 18 years. She was the co-founder, co-CEO and President of Coursera for 5 years, and the Chief Computing Officer of Calico, an Alphabet company in the healthcare space. She is the author of over 200 refereed publications appearing in venues such as Science, Cell, and Nature Genetics, and has an h-index of 130. Daphne was one of TIME Magazine’s 100 most influential people and is a MacArthur Fellow, a member of the National Academy of Engineering, and a Fellow of the American Academy of Arts and Sciences and the International Society of Computational Biology.
In her spare time, Daphne enjoys spending time with her family, especially while traveling to exotic destinations (62 countries so far and counting), where they enjoy hiking, sailing, scuba diving, and eating fresh local food.
Dave did his PhD in biophysics at UCSF and his postdoc at UC Berkeley. He spent 5 years as a high-performance research computing expert at Lawrence Berkeley Labs and at Genentech, where he performed research into Computational Grids including grid system administration and scientific workflow management, to enable scale-out of large computational biology workflows. This was followed by a decade as a Staff Software Engineer at Google, where he was the Founder and Tech Lead of Google Cloud Genomics, and the Founder and Tech Lead of Exacycle, a high-performance platform that enabled scientists to leverage Google’s extensive computational resources to execute and publish state-of-the-art research in protein design, drug discovery, and genomics. He is an author on 27 papers (Nature Chemistry, Biochemistry) and 4 patents.
In his spare time, Dave likes to build cool devices, including microscopes.
Deirdre is a research associate supporting several different aspects of lab work including cloning, iPSC culture, automation, and pretty much anything else needed around the lab!
Deirdre graduated in May 2018 from Cornell University with a BSc. in Biology, concentrating in Genetics, Genomics, and Development. Deirdre is a veteran of lab work having worked in 6 different labs starting at age 15 – most recently as a member of Dr. Kristy Richard’s lab at Cornell University College of Veterinary medicine, and intern at Pfizer in the functional genomics group. She grew up in Nyack, New York and spent many summers in Castle Island, Ireland with her extended family.In her free time Deirdre enjoys live music, podcasts, painting, and fashion design.
Eilon Sharon is a senior data scientist and computational biologist with extensive experience in applying machine learning to decipher various biological questions. Eilon’s work at insitro integrates observations from large population-level studies, such as GWASs, with results from various high throughput in-vitro assays to identify potential drug targets.
After completing a dual major B.Sc. in biology and computer science at TAU, Eilon joined Rosetta genomics, where he worked on discovering miRNA genes in human and predicting their targets. He then earned a PhD from the Weizmann Institute of Science under the supervision of Prof. Eran Segal. During his PhD, he developed synthetic biology Massively Parallel Reporter Assay (MPRA) and statistical and thermodynamic models, which he applied to decipher the encoding of transcriptional regulation in yeast. Following graduation, Eilon transitioned to a postdoc at Profs Jonathan Pritchard and Hunter Fraser labs in Stanford Medical school department of genetics. At stanford, Eilon worked on a diverse set of projects including: detection and fine mapping of genetic associations with T cell receptor V-genes expression; software for transplant health monitoring using cell-free DNA sequencing (which was commercialized by Stanford); and detection of functional genetic variants using a novel high throughput CRISPR editing. Eilon is the author of over 20 refereed publications appearing in venues such as Cell, Nature Biotechnology and Nature Genetics.
In his free time, Eilon enjoys hiking and camping outdoor with his family.
Eric utilizes microscopy to extract quantitative information from cells. His research is focused on developing in situ genomics technologies through a combination of bioengineering, optics, and image analysis. As a member of the functional genomics team, Eric is dedicated to delivering novel assays and datasets to further insitro’s drug discovery pipeline.
Eric earned his Ph.D. in biophysics from Caltech where he developed a new generation of microscopes capable of capturing transcriptomic information from human cells and tissue. Following graduation he transitioned to a postdoc in bioengineering at UCSF/Stanford where he developed synthetic biology tools using CRISPR screens.
In his free time Eric enjoys bicycles, hiking, and spending time with his family.
Selected Publications:Single-cell in situ RNA profiling by sequential hybridization https://www.nature.com/nmeth/journal/v11/n4/full/nmeth.2892.html In situ transcription profiling of single cells reveals spatial organization of cells in the mouse hippocampus https://www.sciencedirect.com/science/article/pii/S0896627316307024 Dynamics and Spatial Genomics of the Nascent Transcriptome by Intron seqFISH https://www.sciencedirect.com/science/article/pii/S0092867418306470
At Insitro, Paolo works within the Data Science and Machine Learning Team, where he applies his academic training in statistical genetics, computational biology and machine learning to identify and characterize functional mechanisms in human disease.
Previously, he was a postdoctoral researcher at Microsoft Research New England, working on automated machine learning and on deep learning models for imagining genetics. Before that, he obtained a PhD in statistical genetics from the University of Cambridge and the EMBL-European Bioinformatics Institute, where he developed new methods for genetic association studies and contributed to international projects such as the last phase of the 1000 Genomes Project and the Blueprint initiative. Previously, he obtained a bachelor’s and master’s degree in physics from the University of Naples, Italy.
In his spare time, Paolo enjoys playing soccer, powerlifting, motorcycling and travelling.
Hervé is a very enthusiastic applied mathematician with strong research interests in molecular and cell biology. His current work at insitro is focused on the development of new computational methods to generate and extract valuable insight from imaging experiments.
Hervé earned a Master of Machine Learning, Computer Vision and applied mathematics from the Ecole Normale Supérieure in Paris before pursuing a PhD at the Pasteur Institute, where he spearheaded the development of FISH-Quant, a software to quantify 3D microscopy images of single RNA molecules, and GRAAL, a Bayesian genome assembler using HiC data. As a postdoc in Robert Tjian’s lab at UC Berkeley, he developed computational methods to improve the quantification of high resolution microscopy data for insight into transcription regulation and spatial genomic organization.
During his free time, Hervé enjoys hiking and giving autographs pretending he is a famous NBA player.
Jason is responsible for building and optimizing insitro’s Research Operations function. He also manages insitro’s internal discovery programs as well as partnered programs with external collaborators.
Prior to joining insitro, Jason spent 15 years at the Novartis Institutes for BioMedical Research in both Oncology and Infectious Diseases groups. His roles spanned portfolio strategy, program management, and scientific operations. During his time in Oncology, Jason helped lead the team that discovered and developed Encorafenib, approved as BRAFTOVI for the treatment of B-Raf mutant melanoma. Prior to NIBR, Jason worked for McKinsey & Company serving primarily Boston area biotech companies. He earned his PhD in Oncology from The Johns Hopkins University School of Medicine.
Jason enjoys the balance of Art with Science and TIG welds steel sculptures.
Dr. Jason Coloma is the CEO of Maze Therapeutics, a company translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Prior to his appointment to CEO, he was Maze’s interim chief operating officer and a venture partner at Third Rock Ventures, where he was instrumental in the founding and launch of the company. As a venture partner at Third Rock, Jason focused on new company creation, and held interim chief business officer roles at insitro and Celsius Therapeutics.
Prior to Third Rock, Jason was senior vice president and chief business officer at Corvus Pharmaceuticals. Previously, he held a number of roles at Roche, including vice president & global therapeutic area head of oncology and cancer immunotherapy partnering. Before joining Roche, Jason was a consultant in the life sciences practice at L.E.K. Consulting. He also worked in finance at Amgen and in research at the University of California, San Francisco and Cytokinetics.
Jason holds a Ph.D. and M.P.H. at the University of California, Berkeley, an MBA from the Tuck School of Business at Dartmouth and a B.S. in biology from the University of San Francisco.
Jeevaa is a Computer Science masters student from University of Toronto. At insitro, Jeevaa focuses on building machine/deep learning models to improve the effectiveness of our high-resolution cellular microscopy platform.
He completed a BSc. in Applied Physics at the University of Toronto before continuing MSc. in Applied Computing at the same institution. He developed an interest in ML during his bachelors which motivated him to pursue it further. During his masters, he worked on various deep learning projects ranging from biomedical image quality enhancement to accent style transfer.
Jeevaa enjoys playing and watching soccer, traveling and spending time with friends.
Jim Tananbaum founded Foresite Capital in 2011 to merge his entrepreneurial experience and networks gained from 25 years in healthcare investing. Throughout his career, he has excelled at systematic and deep technical analysis of healthcare opportunities, while supporting the growth of companies from small enterprises into enduring franchises. Jim designed Foresite Capital to scale his previous experiences. Foresite Capital has grown into a full lifecycle investor with a foundation of technical excellence and a unique culture of internal and external collaboration. Jim’s goal is for Foresite Capital and each of its portfolio companies to deliver important novel products to address critical needs in our healthcare system.
Prior to founding Foresite Capital, Jim co-founded two leading biopharmaceutical companies and two healthcare investment practices. While finishing Harvard University Medical and Business Schools and earning an MS from the Massachusetts Institute of Technology (MIT), he founded GelTex Pharmaceuticals (NASDAQ:GENZ), which brought two drugs to market for less than $80 million. GelTex was acquired in 1998 for $1.6 billion, when its lead drug, Renagel (Renzela) had an annual revenue run rate in excess of $200 million. Today, Renzela is estimated to produce close to $1 billion in annual revenue, 22 years after its launch. Jimalso co-founded and was CEO of Theravance, Inc. which shares GSK’s respiratory franchise through a joint venture, Innoviva (NASDAQ: INVA), and completed a spin-off, Theravance Biopharma, Inc. (NASDAQ: TBPH). The two companies have a combined market capitalization of approximately $3.2 billion.
Jim’s investment experience includes being a founding partner of Prospect Venture Partners II and III, and earlier in his career, a partner at Sierra Ventures, where he helped establish its healthcare services investment practice. Jim has led numerous investments, including Amira Pharmaceuticals (acquired by NYSE: BMS), Amerigroup (NASDAQ: AMGP), Healtheon (NASDAQ:WBMD), and Jazz Pharmaceuticals (NASDAQ: JAZZ). Jim founded Foresite Capital with the vision of marrying elements of all aspects of his career to create a novel investment platform.
As the Head of Process Engineering, John is responsible for leading the development and deployment of lab automation for high-throughput, effective production of high-quality data sets to use in machine learning. John’s team also will focus on building out the tools and capabilities for implementing operational excellence across all of insitro’s laboratories.
Prior to joining insitro, John spent the last 20 years designing, building and managing automation solutions across biotech and pharmaceutical industries. He has significant expertise with early-stage startups, helping to develop, implement and support automation technologies as they scale. John has an M.Eng. in Systems Engineering from Penn State University.
He is an avid outdoor enthusiast who enjoys backpacking, road biking, landscape photography, and travel.
Joyce Yang is a scientist with extensive experience developing novel technologies at the intersection of CRISPR genome engineering, stem cells, and in situ sequencing. To enable machine-learning based drug discovery, her current work at insitro is focused on building CRISPR perturbation platforms in relevant cellular model systems to produce high-quality data from functional genomic screens and disease modeling.
Joyce earned her B.A. from UC Berkeley majoring in Molecular Cell Biology and minoring in Music. She then pursued her passion for science and earned her Ph.D. from Harvard in Biological & Biomedical Sciences. Her graduate work with Dr. George Church focused on developing a novel in situ RNA sequencing technology as well as CRISPR/Cas9 genome engineering strategies to improve efficiency in human induced pluripotent stem cells (iPSCs). Next, she dived into the exciting world of biotech startups at Synthego, contributing to the growth and commercialization of the new Cell Engineering division as one of the foundational scientists.
Joyce loves to sing and experiment on the piano, traveling, backpacking, taking long walks, and trying all things chewy.
As the Office Manager/Administrative Assistant at insitro, Kate brings with her extensive knowledge and experience in Office Management and Executive Assistant roles in the finance and life sciences industries in the Bay Area. She is passionate about supporting and motivating mission-driven team members in a culture based on integrity and optimism.
Prior to joining insitro, Kate was a Sr. Executive Assistant at Immune Design, a small late stage immunotherapy company, acquired by Merck in 2019, where she helped with daily operations and workflow along with vendor and investor relations. Before then, Kate was an Office Manager at Northwestern Mutual, an investment services company, where she held roles of increasing responsibility, while supporting the organization’s tripling in size and creating an amazing culture and environment.
Kate holds a bachelor’s degree in Law, Transportation and Mobility Management from Romania and completed multiple Fred Pryor courses for Management, Supervision & Leadership.
In her free time, Kate enjoys and participates in all kinds of activities that keep her active. She loves to travel with a preference to exotic and tropical destinations. She speaks English, Hungarian, Romanian (born and raised in Transylvania) and is conversational in Spanish and Italian.
Kathryn is a data engineer with a background in the microbiome and cloud computing. At insitro Kathryn is working with the data engineering, and data science and machine learning teams to build and scale data analysis pipelines in the cloud.
Before joining insitro, Kathryn worked at Second Genome building metagenomics pipelines and analyzing microbiome data. Kathryn received her Master’s in Bioinformatics from the University of Michigan and worked in Pat Schloss’ lab on projects in microbial ecology, clostridium difficile, and colorectal cancer.
In her free time, Kathryn enjoys playing and watching hockey, traveling, and scuba diving.
As Senior Vice-President of Drug Discovery, Keith is responsible for machine learning-enabled drug discovery programs at insitro. Keith and his team are both establishing new drug design capabilities, exploiting the power of machine learning models, and undertaking drug discovery programs on molecular targets derived via the insitro-human (ISH) target discovery platform.
Keith has over three decades of drug discovery experience, building and leading research enterprises ranging from handfuls to hundreds of scientists, tackling programs across a wide range of therapeutic areas, and employing a panoply of therapeutic modalities. During his career, Keith, and the organizations he has led, have delivered over thirty clinical candidates, across fifteen therapeutic areas, many of which have reached Phase 2, and two of which are in the hands of physicians treating patients today – eletriptan (Relpax®) for migraines and maraviroc (Selzentry®) for HIV infections.
Before joining insitro, Keith was President of the Ferring Research Institute in San Diego, engaged in the discovery of peptide therapeutics. Before joining Ferring, Keith had a long career at Pfizer, leading discovery research at three different sites across the US and UK, heading the company’s R&D strategy team, and running a laboratory as a visiting investigator at The Scripps Research Institute.
Keith completed his academic and postdoctoral studies at Imperial College London, The University of Cambridge (Raphael lab), Stanford University (Johnson lab), and Columbia University (Stork lab).
In his free time, Keith enjoys cycling, jogging, reading, writing and mechanical watches.
Kelly Haston is a stem cell biologist with broad experience in human stem cell-based models of development and disease. She is a Sr. Scientist in the disease modeling group helping guide the team as they build biological model systems that will interface with the genetic, data science and machine learning modules of insitro’s unique approach to discover novel human therapeutics.
Kelly was born in Ottawa and grew up in central British Columbia and Toronto, Canada. She did her undergraduate and masters work at the UC Berkeley studying the effects of pesticides on frog gonad development. She then began working in the stem cell field during her Ph.D. with Dr. Renee Rejio Pera at UC San Francisco and Stanford University. Kelly performed postdoctoral positions briefly with Dr. Lee Rubin at Harvard and then with Dr. Steven Finkbeiner at UCSF’s Gladstone Institutes where she focused on building stem cell based models of neurodegeneration. She transitioned to industry in 2017, taking a position with a small start up, Scaled Biolabs, as Lead Scientist where she used the company’s novel discovery platform to optimize the production of many different cell types from human stem cells.
Kelly uses her spare time to be outside as much as possible, mainly trail running or fastpacking. She also loves reading, traveling to new places and attending live music and performances.
Dr. Krishna Yeshwant is a physician, programmer, and entrepreneur who has been working with GV since its inception. He first joined Google as part of the New Business Development team.
Prior to Google, Krishna helped start an electronic data interchange company that was acquired by Hewlett-Packard and a network security company that was acquired by Symantec.
Krishna has a B.S. in computer science from Stanford University. He also earned an M.D. from Harvard Medical School, an MBA from Harvard Business School, and completed his residency at Brigham and Women’s Hospital in Boston, Massachusetts where he continues to practice.
Lauren is part of the Automation & Process Engineering team. She helps develop and implement lab processes, oversees the purchasing and inventory management of lab supplies, and manages shipping and receiving.
After obtaining her B.S. in Pharmaceutical Chemistry from UC Davis, Lauren decided to explore the operations side of science and worked at Calico Life Sciences, an Alphabet company, as a member of the lab operations team.
In her spare time, Lauren enjoys doing puzzles, playing volleyball, baking, and spending time with her border collie who doesn’t know what sleep is.
Lorn Kategaya is a cell biologist with small molecule drug discovery experience. At insitro, Lorn will develop relevant disease assays and utilize genetic/chemical screens to identify key biological players that modulate disease outcomes.
Lorn has a PhD in pharmacology from the University of Washington, a post-doc from UCSF and industry experience at Genentech and IDEAYA Biosciences.
Away from the bench, Lorn follows politics and enjoys live music, theatrical performances, and french fries.
Selected Publications:Werner Syndrome Helicase is Required for the Survival of Cancer Cells with Microsatellite Instability https://www.cell.com/iscience/fulltext/S2589-0042(19)30040-9 USP7 small-molecule inhibitors interfere with ubiquitin binding https://www.nature.com/articles/nature24006
Matthew Albert is Vice President of Immunology & Infectious Diseases at insitro.
Prior to joining insitro, Matthew worked as Principal Scientist in the Department of Cancer Immunology at Genentech (2015 – 2019); and served as Professor (2003 – 2015), Founder and Director of the Center for Human Immunology (2007 – 2015) and Director of the Immunology Department at Institut Pasteur, Paris France (2010 – 2015).
Matthew is an immunologist and clinical pathologist, with a long-standing interest in immune regulation and tumor immunity. His research embraces the power of a “human-first” approach to scientific discovery, driven by a commitment to understand how to achieve effective response to cancer immunotherapy, autoimmunity and chronic infection while limiting adverse effects of treatment. As this requires a deep insight into health and disease pathogenesis, he has developed several areas of investigation over the last two decades, which has included a deep commitment to bladder diseases (incl. cancer and UTI); and liver diseases (incl. HCV, HBV, HCC and NASH). He has also been a leader in the Milieu Intérieur Consortium, a 30-team academic / industrial partnership that aims to define the genetic, microbiome and environmental determinants of variable immune responses in healthy persons.
Matthew trained at The Rockefeller University, Cornell University Medical College and did his residency at New York Presbyterian Hospital. He is the author of more than 100 peer-reviewed scientific papers and has made major contributions to the understanding of antigen cross-priming and the impact of post-translational modification of chemokines as determinants of effective tumor immunity. In his spare time, he and his family enjoy cooking together, traveling and exploring the world’s ecology under the sea (marvelling at Ostracod mating practices in the Carribean), in jungles (visits to the Sarawak Biodiversity Centre in Borneo), and in ecology parks (riding dolphins in Tunisia). The have traveled together to over 35 countries, with a strong belief that knowing and engaging with diverse communities and cultures help them be better contributors to the world.
Selected Publications:Germline genetic polymorphisms influence tumor gene expression and immune cell infiltration. Lim YW, Chen-Harris H, Mayba O, Lianoglou S, Wuster A, Bhangale T, Khan Z, Mariathasan S, Daemen A, Reeder J, Haverty PM, Forrest WF, Brauer M, Mellman I, Albert ML. Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):E11701-E11710. doi: 10.1073/pnas.1804506115. Epub 2018 Nov 21 Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, Alanio C, Scepanovic P, Hammer C, Jönsson F, Beitz B, Quach H, Lim YW, Hunkapiller J, Zepeda M, Green C, Piasecka B, Leloup C, Rogge L, Huetz F, Peguillet I, Lantz O, Fontes M, Di Santo JP, Thomas S, Fellay J, Duffy D, Quintana-Murci L, Albert ML; Milieu Intérieur Consortium. Nat Immunol. 2018 Mar;19(3):302-314. doi: 10.1038/s41590-018-0049-7. Epub 2018 Feb 23 Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human Populations. Quach H, Rotival M, Pothlichet J, Loh YE, Dannemann M, Zidane N, Laval G, Patin E, Harmant C, Lopez M, Deschamps M, Naffakh N, Duffy D, Coen A, Leroux-Roels G, Clément F, Boland A, Deleuze JF, Kelso J, Albert ML, Quintana-Murci L. Cell. 2016 Oct 20;167(3):643-656.e17. doi: 10.1016/j.cell.2016.09.024 RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8⁺ T cells. Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C, Green DR, Oberst A, Albert ML. Science. 2015 Oct 16;350(6258):328-34. doi: 10.1126/science.aad0395. Epub 2015 Sep 24
Matt mostly finished his MSc in Machine Learning at the Montreal Institute for Learning Algorithms. Previously, he obtained a BSc and MSc in Mathematics and Statistics from the University of Toronto. He most recently worked as a machine learning engineer at a Toronto startup and as a researcher at Huawei. He specifically worked in the fields of natural language processing and visual question answering.
Previous to that, Matt advised statisticians at the university and was briefly a lecturer. Before that, he applied machine learning to classify animal behaviour for a genetics lab. He is happy to be once again working in biology; tackling problems whose solutions can make a huge difference.
In his spare time, Matt likes to follow current events, watch movies and think about how to make artificial general intelligence.
As Disease Modeling Scientist, Max is focused on using pluripotent stem cells, CRISPR, and a range of differentiation and transcriptomics approaches to model human diseases in in vitro platforms. Max and his team will model devastating human diseases using the relevant cell types, and will produce high-throughput / high-quality imaging and transcriptomic datasets for insitro’s machine learning platform to mine for phenotypes.
Max is an engineer by training, gaining a B.S. in Engineering Mechanics and Astronautics and a Ph.D. from the Materials Science Program of the University of Wisconsin – Madison. By combining dry lab engineering with wet lab disease modeling, Max has frequently used the newest technologies to gain insights into the mechanisms by which various genetic diseases affect human health. Max spent his time in graduate school developing micropatterned differentiation techniques and computational analysis tools to improve stem-cell-based heart modeling methods. Prior to joining insitro, Max spent 4 years as a postdoc in the Novartis Neuroscience department, where he developed single cell characterization platforms to discover disease mechanisms of tuberous sclerosis, uncovered novel mechanisms of disease progression in certain dementias, and conducted genome-wide screens to elucidate potential Zika virus receptors.
Max’s free time is spent with his border collie, Coda, along with playing piano/guitar, and poorly-but-enthusiastically playing various sports.
Selected Publications:Genetic ablation of AXL does not protect human neural progenitor cells and cerebral organoids from Zika virus infection https://www.ncbi.nlm.nih.gov/pubmed/27912091 Micropattern width dependent sarcomere development in human ESC-derived cardiomyocytes https://www.ncbi.nlm.nih.gov/pubmed/24582552 p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells https://www.ncbi.nlm.nih.gov/pubmed/29892062/
Mei is a Research Associate in High-Throughput Biology and her work primarily focuses on differentiate human pluripotent stem cell (iPSC) into desired cell types for in vitro human disease modeling and generate datasets for insitro’s machine learning platform.
Prior to joining insitro, Mei was a CIRM (California Institute for Regenerative Medicine) Scholar at the Gladstone Institute working on iPSC neurodegenerative diseases modeling. Mei obtained her B.Sc. in Biology with an emphasis on cellular/molecular biology and a minor in chemistry from Humboldt State University.
In her spare time, Mei enjoys photography, visit art exhibits, live music and performances, reading, hiking, exploring new places and try different cuisines.
Mohammad ‘Muneeb’ Sultan is a computational chemist with experience working at the interface of computational biophysics, free-energy methods, machine learning, and statistical mechanics. His current work at insitro is focused on building up the machine learning platform, and designing novel methods for analyzing the outputs of various high throughput assays.
Muneeb is a native of Pakistan and grew up in the city of Rawalpindi. He got his undergraduate degree in Chemistry at Yale, and his PhD in Physical Chemistry at Stanford under Vijay Pande. At Stanford, Muneeb focused on studying oncogenic kinases using the Folding@home distributed computing platform, collecting and analysing some of the largest simulation datasets of their kind. Simultaneously, he also worked on developing new Machine learning algorithms for accelerating free-energy calculations and molecular simulations. Muneeb has co-authored 17 publications appearing in venues such as PRE, PNAS, Nature Scientific Reports, and Nature Chemistry.
During his free time, Muneeb likes to powerlift, do yoga, explore the bay area, create digital art, cook, and listen to music.
Nav has extensive experience working at the intersection of next generation sequencing, microfluidics, and single cell technologies. His focus at insitro involves designing and analyzing high throughput sequencing experiments in order to support indication specific drug discovery pipelines and the functional genomics team.
Nav acquired his undergraduate degree in Chemical Engineering at UC Berkeley followed by a PhD in Biological Engineering at MIT. His graduate research focused on developing novel targeted sequencing technologies to make single cell genomic experimental more feasible and to understand patterns of DNA damage. While completing his PhD, Nav also served as a Communication Fellow at the Broad Institute where he mentored scientists through the process of written, verbal, and visual presentations of science.
In his free time, Nav is an avid proponent of indoor and outdoor sports ranging from lounging on a couch to climbing up and skiing down mountains.
Owen spent four and a half years as a member of Dr. Jonathan Weissman’s Lab at UCSF, where he supported the development RNAi-based and CRISPR-based mammalian genome-scale functional genomics screening platforms, successfully identifying new targets for grants and publications. He cloned and maintained ultracomplex shRNA/sgRNA screening libraries as well as generated stable cell lines with gene repression or activation. Additionally, he conducted numerous functional genomic screens in cancer cell lines challenged by various toxins, drugs, and chemicals.
After his time at UCSF, he spent two and a half years at Driver, where he developed NGS assays and validated tumor-normal and cfDNA manual assays under CAP and CLIA guidelines. He also had fun acquiring a new set of skills in converting these manual assays into fully automated processes.
Academic affiliations and titles: Core Institute Member, Broad Institute of Harvard and MIT; Karl Van Tassel
(1925) Career Development Associate Professor of Biological Engineering, Massachusetts Institute of
Technology; Extramural Faculty Member, Koch Institute for Integrative Cancer Research at MIT
Dr. Blainey took degrees in mathematics and chemistry at the University of Washington before joining Professors Gregory L. Verdine and X. Sunney Xie in the Department of Chemistry and Chemical Biology at Harvard University for Ph.D. study in Physical Chemistry. There, Dr. Blainey developed single-molecule biophysics techniques for the study of DNA repair. In 2007, Dr. Blainey shifted his focus to single-cell genomics in Professor Stephen R. Quake’s group at Stanford University. A faculty member in Biological Engineering at MIT and a Core Member of the Broad Institute since 2012, Dr. Blainey’s group integrates microfluidic, molecular, and imaging tools to create robust and scalable solutions to major challenges in the life sciences and biomedicine.
Perry is a Special Projects Manager and member of the Data Science team at insitro. He supports the executive team on initiatives at the intersection of machine learning and corporate strategy, including business development and the formulation of machine learning problems relevant to drug discovery and development.
Perry completed his Ph.D. in the Bioinformatics and Integrative Genomics program at Harvard Medical School where his research focused on using statistical models to predict protein structure from sequence variation. Prior to graduate school he spent five years working in finance for Morgan Stanley and BMGI, the investment office of Bill and Melinda Gates and the Bill and Melinda Gates Foundation. He majored in physics at Princeton University where his senior thesis focused on modeling viral gene regulatory circuits.
Having grown up in Sun Valley, ID, Perry is excited to be back west and enjoys spending as much time as possible outside, whether on foot, bike, or skis.
At Third Rock, Reid brings over 20 years of operating experience in the biotechnology industry to focus on the formation, development and strategy of our portfolio companies. Reid was a member of the founding scientific team at Incyte in 2002, and most recently served as the company’s executive vice president and chief scientific officer. Prior to Incyte, Reid held positions of increasing responsibility at Dupont Pharmaceuticals and Bristol-Myers Squibb. Reid received his B.S. in molecular genetics and biochemistry from Murray State University and his Ph.D. in human molecular genetics from Washington University School of Medicine in St. Louis. He conducted his postdoctoral training at the National Institutes of Health.
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing, and development of more than thirty companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL; Ikaria; Kythera Biopharmaceuticals (KYTH); Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics; KSQ Therapeutics, Beam, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation.
Robert is a director of Vir Bio, GRAIL, Juno Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
Srinivasan is an MSc in Applied Computing candidate in the Department of Computer Science at the University of Toronto. His research interests are machine learning and image processing for computer vision and healthcare applications. His work at insitro involves developing learning models for the efficient analysis of our high-throughput microscopy platform.
During his Master’s program at the University of Toronto, he has worked on various machine learning projects, such as early prediction of sepsis onset and adversarial imitation learning by planning. Prior to this, he was a Lead Engineer in the Medical Imaging team at Samsung Research, India working on ultrasound imaging applications. Srinivasan holds a dual degree (Bachelors + Masters) in Biotechnology and Biochemical Engineering from the Indian Institute of Technology, Kharagpur.
In his free time, Srinivasan enjoys singing, hiking and reading books.
As Executive Assistant to the CEO, Steve performs an extensive array of administrative tasks and sets a foundation for the smooth business operations of the company, making the entire team more effective and successful.
Steve spent his first nine years in Bay Area biotech at Amyris, moving from receptionist to executive support roles for the CEO and the President of R&D. He then moved to Calico to support Daphne Koller in her role as Chief Computing Officer. Steve has an M.A. in French from the University of Louisville and a B.A. in Foreign Languages/International Studies from Bellarmine University.
Steve used to have many hobbies but now has three young daughters.
As part of the Functional Genomics team at insitro, Tina generates libraries for screening using the latest molecular biology techniques.
Tina spent the last thirteen years working in all facets of yeast strain engineering, first at Amyris and then at Lygos and Calico. She received a B.S. in Chemical Engineering from UC-Berkeley and was an undergraduate researcher in the Keasling lab.
Tina used to play ice hockey but now focuses her energy into knitting or crocheting toys for her three kids.
Vijay Pande is a general partner at Andreessen Horowitz where he leads the firm’s investments in companies at the cross section of biology and computer science including areas such as the application of computation, Machine Learning, and Artificial Intelligence broadly into Biology and Healthcare as well as the application of novel transformative scientific advances.
Previously, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University. He led a team of researchers pioneering computational methods and their application to medicine and biology, resulting in over 200 publications, two patents and two novel drug treatments. Concurrently, he was the director of the Biophysics program at Stanford, where he led a team of more than 50 Stanford faculty members and propelled the program to the top in the country.
As an entrepreneur at the convergence of biology and computer science, Vijay is the founder of the Folding@Home Distributed Computing Project for disease research that pushes the boundaries of the development and application of computer science techniques (such as distributed systems, machine learning, and exotic computer architectures) into biology and medicine, in both fundamental research as well as the development of new therapeutics. Also during his time at Stanford, Vijay co-founded Globavir Biosciences, where he translated his research advances at Stanford and Folding@Home into a successful startup, discovering cures for Dengue Fever and Ebola. In his teens, he was the first employee at video game startup Naughty Dog Software, maker of Crash Bandicoot.
Vijay received a BA in Physics from Princeton University and a PhD in Physics from MIT. He was awarded the DeLano Prize in Computation, Guinness World Record for Folding@Home, ACS Thomas Kuhn Paradigm Shift Award, and MIT TR100.
He serves on the board of the following Andreessen Horowitz portfolio companies: Apeel, BioAge Labs, Freenome, Omada Health, Patient Ping, and Rigetti Computing. He also leads the firm’s investments in Benchling, Cardiogram, SolveBio, TL Biolabs, TwoXAR, Q.bio, and uBiome.